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Abstract
Recently, we discovered autoantibodies against the amino (NH2)-terminal ofα-enolase (NAE) in patients with Hashimoto's encephalopathy (HE)
(83.3%; 5/6) [Fujii, A., Yoneda, M., Ito, T., Yamamura, O., Satomi, S., Higa, H., Kimura, M., Suzuki, M., Yamashita, M., Yuasa, T., Suzuki, H.,
Kuriyama, M., 2005. Autoantibodies against the amino terminal of α-enolase are a useful diagnostic marker of Hashimoto's encephalopathy.
J. Neuroimmunol. 162, 130–136]. We further investigated the anti-NAE autoantibodies i 25 patients who fit the diagnostic criteria for HE, based on
the presence of anti-thyroid antibodies and responsiveness to immunotherapy. In this study, we demonstrated a high prevalence (68%, 17 of 25) and
high specificity of anti-NAE autoantibodies in patients with HE, and clarified the clinical features of HE. This result demonstrated that anti-NAE
autoantibodies, in addition to anti-thyroid autoantibodies, are emphasized as useful serological diagnostic markers of HE.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Hashimoto's thyroiditis (HT) is the most common disorder
affecting the thyroid gland. In 1966, Brain et al. reported the
first case of encephalopathy associated with HT, who presented
with recurrent neuropsychiatric symptoms accompanied by
serum anti-thyroid antibodies in euthyroid states (Brain et al.,
1966). Hashimoto's encephalopathy (HE) therefore was recog-
nized as a nomenclature of new disease, distinct from myxo-
edema encephalopathy associated with hypothyroidism (Behan
et al., 1988; Shaw et al., 1991; Chaudhuri and Behan, 2003;
Chong et al., 2003).
Autoimmune mechanism has been proposed as an underly-
ing pathogenesis (Brain et al., 1966; Chaudhuri and Behan,
2003; Chong et al., 2003), and immunotherapy such as steroids,
immunosuppressants and/or intravenous injection of immuno-
globulin (IVIg)/plasmapheresis was successfully administered
(Shaw et al., 1991; Boers and Colebatch, 2001; Chaudhuri and
Behan, 2003). Over 100 accumulated cases (Shaw et al., 1991;
Chaudhuri and Behan, 2003; Chong et al., 2003) reported
mainly by neurologists, emphasized this potentially treatable
encephalopathy associated with HT in the differential diagnosis
of unknown etiology of encephalopathy, and suggested the risk
of under-diagnosis of HE (Ghika-Schmid et al., 1996; Maydell
et al., 2002).
Several diagnostic criteria for HE have been proposed based
on encephalopathy, the presence of anti-thyroid antibodies and/
or responsiveness to immunotherapy including steroids (Shaw
et al., 1991; Peschen-Rosin et al., 1999). Endocrinologists
however argued against the terminology of HE because of the
wide spectrum clinical features in patients with HE and the high
prevalence of anti-thyroid antibodies in the normal population,
which are usually subclinical (Sawka et al., 2002; Fatourechi,
2005).
To resolve such debates on the nomenclature and nature of
HE, more specific diagnostic markers are needed (Chong et al.,
2003; Fatourechi, 2005). Very recently, we discovered autoanti-
bodies against the amino (NH2)-terminal of α-enolase (referred
to as NAE) that were highly specific in sera from a limited
number of HE patients (83%, 5 of 6 with HE; 11%, 2 of 17 with
HT without any neuropsychiatric features; none of controls [50
individuals] including those with other neurological or immu-
nological conditions involving encephalopathy [25 individuals])
(Fujii et al., 2005). Thus, the anti-NAE autoantibodies are a
potential tool for the diagnosis of HE and resolving the debate
Journal of Neuroimmunology 185 (2007) 195–200
www.elsevier.com/locate/jneuroim
⁎ Corresponding author. Tel.: +81 776 61 8351; fax: +81 776 61 8110.
E-mail address: myoneda@fmsrsa.fukui-med.ac.jp (M. Yoneda).
0165-5728/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.jneuroim.2007.01.018
Au
th
or
's 
  p
er
so
na
l   
co
py
over HE described above.We further investigated the prevalence
and specificity of anti-NAE autoantibodies, and clarified the
clinical features in a large number of patients with HE in this
study.
2. Patients and methods
2.1. Patients
In this study, we selected 25 patients with HT, who presented
with encephalopathy and fit the diagnostic criteria for HE, based
on the presence of anti-thyroid antibodies and responsiveness to
immunotherapy such as steroids, immunosuppressants and/or
IVIg/plasmapheresis. These 25 patients included our own 8 cases
and 17 cases from other institutions. Neurological specialists
carefully excluded other possible causes of encephalopathy in-
cluding infections, other autoimmune conditions, vitamin defi-
ciency, intoxication, cerebrovascular diseases, neoplasms and
Creutzfeldt–Jakob disease and so on, and the detailed clinical
information of each patient was obtained from the attending
physician. The ethics committee of the University of Fukui
approved this research, and written permission was obtained
from each patient.
The clinical profiles of all patients were summarized in
Table 1 and Fig. 1. The sex ratio of patients examined was 7:18
(male:female). The mean age was 60 years old (range: 23 to 83).
All patients showed the responsiveness to steroids in variable
degrees. We categorized the patients into three clinical forms
such as acute encephalopathy (AE)-form, subacute psychiatric
(SP)-form and others. AE was the most common clinical form
(76%; 19 of 25), SP was much less frequent (16%; 4 of 25), and
others were 8% (2 of 25). Four of 25 patients demonstrated
recurrence (16%). Five of 25 patients had a history of HT before
encephalopathy appeared (20%). All patients carried anti-thy-
roid antibodies (both of anti-thyroglobulin [Tg] and anti-thyroid
peroxidase antibodies [TPO], 48%, 12 of 25; anti-Tg, 32%, 8 of
25; anti-TPO, 20%, 5 of 25). Most of the patients were in
euthyroid states (72%, 18 of 25), except for a few patients in
mild hypothyroid states treated with thyroxin (16%, 4 of 25) or
transient hyperthyroid states (thyrotoxicosis) (12%, 3 of 25). All
of the patients showed neuropsychiatric symptoms after re-
covery from dysthyroid states.
Table 1
Clinical features and anti-NAE autoantibodies in patients with Hashimoto's encephalopathy
Patient Age/
gender
Clinical
form
Anti-
thyroid
Immunotherapy (response) Anti-
NAE
Neurological manifestation Abnormal
EEG
Abnormal
brain
MRI
Elevated
CSF/
IgG
protein
C S C/P I A
1 44, F AE TPOa PSL (excellent) Positive + + + Chorea − + − +
2 34, M AE TPO, Tg mPSL/PSL (excellent) Positive + + + − − + − −
3 71, F AEb TPO, Tg a mPSL/PSL (excellent) Positive + + + − − + − +
4 45, F AE TPO, Tg mPSL (excellent) Positive + + − Tremor − n.d. − −
5 60, F AE Tg PSL (excellent) Positive + − + − − + − +
6 78, F AE Tg c PSL (excellent) Positive + + − Myoclonus − + − +
7 32, F AE (LE) TPO,Tg mPSL/PSL (excellent) Positive + + + − − + L −
8 57, F AEb TPOa PSL (excellent) Positive + + + Chorea + + − −
9 78, F AE Tg PSL (excellent) Positive + − + Tremor − + − +
10 83, F AE TPO, Tg mPSL/PSL (good) Positive + + − − − + − −
11 76, M AE TPO, Tg c PSL (good) Positive + + − Myoclonus − + − +
12 79, F AE TPO, Tg c PSL (good) Positive + − + Chorea − + − −
13 36, F AE Tg mPSL/PSL (good) Positive + + + − − + − −
14 71, F AEb Tg mPSL (fair) Positive + + + Myoclonus − + WM n.d.
15 56, M AE Tg d mPSL/PSL (good) Negative + + + − − + − +
16 74, M AE Tg d mPSL/PSL (good) Negative + + − − − n.d. − +
17 69, M AE (LE) TPO mPSL/PSL (good) Negative + + + Myoclonus − + L −
18 58, F AE (LE) TPO, Tg d mPSL (good) Negative + + + Myoclonus − + L −
19 61, F AE (LE) TPO, Tg d mPSL/PSL (fair) Negative + + + − − − L −
20 69, F SP TPOa PSL (good) Positive − − + − − n.d. − +
21 60, M SP TPO, Tg PSL (fair) Positive − − + − − + − +
22 69, F SP TPO PSL (fair) IVIg (excellent) Positive − − + Myoclonus − + − n.d.
23 61, M SP TPO, Tg PSL (excellent) Negative − − + − + + − +
24 63, F CJDb Tg a mPSL/DX/azathioprine (excellent) Negative + + + Myoclonus + + (PSD) − +
25 23, F IVM TPO, Tg PSL (excellent) Negative − − − Myoclonus − − − −
AE, acute encephalopathy form; SP, subacute psychiatric form; LE, limbic encephalopathy-like clinical feature; CJD, Creutzfeldt–Jakob disease-like clinical feature;
IVM, involuntary movement dominant-form; TPO, anti-thyroid peroxidase antibodies; Tg, anti-thyroglobulin antibodies; mPSL, methylprednisolone; PSL, predni-
solone; DX, dexamethasone; IVIg, intravenous administration of immunoglobulin G; C, consciousness disturbance; S, seizures; C/P, cognitive impairment/psychiatric
symptoms; I, involuntary movements: A, ataxia; PSD, periodic synchronized discharge-like paroxysmal discharges; L, limbic lesions; WM, white matter lesions. n.d.
not determined. Patients 1, 3, 8, 14, 20 and 24 were very briefly reported (Fujii et al., 2005).
a Known history of Hashimoto's thyroiditis before the onset of encephalopathy.
b Positive history of recurrence.
c Transient hyperthyroidism (thyrotoxicosis).
d Hypothyroidism treated with thyroxin.
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We examined anti-thyroid antibodies (anti-Tg and anti-TPO),
steroid-responsiveness, clinical features (consciousness disturbance
[C], seizures [S], cognitive impairment/psychiatric symptoms
[C/P], involuntary movements [I], ataxia [A]), electroencepha-
logram [EEG], brain MRI and protein/immunoglobulin G in
CSF, and compared these between patients with anti-NAE
autoantibodies [referred to as NAE(+)] and without [NAE(−)].
Steroid-responsiveness was evaluated in three degrees: excellent,
good, and fair.
2.2. SDS-PAGE and immunoblotting
Anti-NAE autoantibodies were investigated in encephalo-
pathic patients with HT and patients with other disorders
including autoimmune conditions or collagen diseases. Immuno-
blotting analysis of the patient's serum against theNAE expressed
in human cultured cells was carried out with 12% sodium lauryl
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) using a
gel electrophoresis system (BE-220, BIOCRAFT, Tokyo, Japan),
described previously (Fujii et al., 2005). The proteins on the gel
were Western-blotted onto polyvinylidene difluoride (PVDF)
membrane (Hybond-P, Amersham Biosciences, NJ) with a
blotting apparatus (KS-8453, Oriental Instrument, Tokyo,
Japan) at 0.3 mA/cm2 for 8 h at 4 °C. For detection of the band
specific to NAE, serum was applied to the membrane and in-
cubated in 1% gelatin for 1 h at room temperature, then horse-
radish peroxidase (HRP)-conjugated anti-human goat IgG Fc
(ICN Pharmateuticals, Inc., OH) was applied to the membrane as
the secondary antibody, fluoresced, and developed onX-ray films
(BioMax, Kodak, NY).
2.3. Statistical analysis
We used χ2 test to assess the correlation between patients
with encephalopathy with HT and anti-NAE antibodies.
3. Results
3.1. Anti-NAE autoantibodies
The clinical profiles of patients and immunological char-
acters were summarized in Table 1 and Fig. 1. Of the 25 patients
with encephalopathy with HTexamined here, 68% of them were
NAE(+) (17 of 25) (pb0.001, compared to patients with HT
without encephalopathy [10%, 2 of 20], supplemented by addi-
tional data from 3 patients of HTwithout encephalopathy to our
previous study) (Fujii et al., 2005). To our knowledge, there
Fig. 2. Immunoblotting of the recombinant NAE with sera from patients with encephalopathy with HT, HT without encephalopathy, Basedow's disease or other
neurological disorders including autoimmune conditions, or from controls. HE, Hashimoto's encephalopathy; 3–23, patients 3–23 with HE in Table 1; HT,
Hashimoto's thyroiditis without encephalopathy; Ba, Basedow's disease; HC, healthy controls; ADEM, post-infectious acute disseminated encephalomyelitis; En,
viral encephalitis; CJD, Creutzfeldt–Jakob disease; MS, multiple sclerosis; MG, myasthenia gravis; Hu, paraneoplastic syndrome associated with Hu-antigen; RA,
rheumatoid arthritis; SLE, systemic lupus erythematosus; SjS, Sjögren syndrome; B-d, Behçet disease; MCTD, mixed connective tissue disease. MW, molecular
weight marker. ⁎The position of the recombinant NAE. #Derivatives from human cultured cells for expression, which showed non-specific reactions with sera.
Fig. 1. Clinical profiles of patients. AE, acute encephalopathy form; SP,
subacute psychiatric form; HT, Hashimoto's thyroiditis. Tg, anti-thyroglobulin
antibodies; TPO, anti-thyroid peroxidase antibodies.
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were no sera from 33 patients with 2 Basedow's disease, 4 post-
infectious acute disseminated encephalomyelitis (ADEM), 2
viral encephalitis, 2 Creutzfeldt–Jakob disease, other autoim-
mune disorders or collagen diseases with neurological symp-
toms, including 4 multiple sclerosis, 4 myasthenia gravis, 2
paraneoplastic neurological syndrome associated with Hu-
antigen, 2 rheumatoid arthritis, 3 systemic lupus erythematosus,
3 Sjögren syndrome, 3 Behçet disease, 2 mixed connective
tissue disease that showed any immunological reaction to the
recombinant NAE (Fig. 2). This confirmed our recent finding
that anti-NAE autoantibodies were highly specific to HE.
3.2. Neurological manifestations
The neurological manifestations of patients are summarized in
Table 1 and Fig. 3. There is no significant difference in the
responsiveness to steroid between NAE(+) (excellent, 9; good, 5;
fair 3) and NAE(−) patients (excellent, 3; good, 4; fair 1) but a bit
better response in NAE(+) (Table 1 and Fig. 3). Consciousness
disturbance appeared most frequently (80%, 20 of 25; 82%, 14 of
17 in NAE(+), 75%, 6 of 8 in NAE(−)). Seizures were also
common (68%, 17 of 25; 64%, 11 of 17 in NAE(+), 75%, 6 of 8 in
NAE(−)). Cognitive impairments/psychiatric symptoms such as
memory disturbance, abnormal behaviors or hallucination
occurred in 76% (19 of 25; 76%, 13 of 17 in NAE(+), 75%, 6
of 8 in NAE(−)). Involuntary movements including myoclonus/
tremor and chorea were also present (52%, 13 of 25) with no
difference between NAE(+) (52%; 9 of 17) and NAE(−) (50%; 4
of 8). Ataxia was much less frequent (12%, 3 of 25 in total; 5%, 1
of 17 in NAE(+); 25%, 2 of 8 in NAE(−)).
3.3. Laboratory and MRI findings
The laboratory and MRI findings of patients were summa-
rized in Table 1 and Fig. 4. EEG abnormalities such as slow
background activities and/or episodic spikes/slowwaves showed
very high prevalence (90%, 20 of 22) in patients examined, with
a difference between NAE(+) (100%, 15 of 15) and NAE(−)
(71%, 5 of 7) (pb0.05). By contrast, abnormalities on brainMRI
were much less frequent (20%, 5 of 25), with no difference
between NAE(+) (11%, 2 of 17) and NAE(−) (37%, 3 of 8). The
elevated protein/immunoglobulin G in CSF was present (54%,
12 of 23), with no difference betweenNAE(+) (53%, 8 of 15) and
NAE(−) (50%, 4 of 8).
4. Discussion
After Brain et al. reported the first case of encephalopathy
associated with HT, there has been a debate on the nosology and
nature on HE, despite the accumulation of over 100 reported
cases (Behan et al., 1988; Chaudhuri and Behan, 2003; Chong
et al., 2003). It is because of the wide spectrum clinical features
in patients with HE, the high prevalence of anti-thyroid anti-
bodies in the normal population (e.g. 5–10% in male, 10–25%
in female in Japan), and the lack of specific diagnostic marker.
HE patients presented with a variety of clinical features such as
acute encephalopathy, psychosis/cognitive impairment, ataxia,
recurrent acute disseminated encephalomyelitis (ADEM), in-
voluntary movements (chorea, myoclonus or tremor) and
Creutzfeldt–Jakob disease-like clinical features (Behan et al.,
1988; Chaudhuri and Behan, 2003; Chong et al. 2003; Ferracci
et al., 2004; Fatourechi, 2005).
In this study, the patients who presented with encephalopathy
and fit the criteria for HE based on the presence of anti-thyroid
antibodies and the responsiveness to immunotherapy such as
steroids, immunosuppressants and/or IVIg/plasmapheresis, de-
monstrated a high prevalence of anti-NAE autoantibodies in
their sera (68%; 17/25; pb0.001, compared to patients with HT
without encephalopathy [10%, 2/20]). This strongly supported
our previous finding of a high prevalence (83%, 5 out of 6) of
anti-NAE autoantibodies in patients with HE (Fujii et al., 2005).
There were no sera from patients with other disorders including
autoimmune conditions or collagen diseases that showed any
immunological reaction to recombinant NAE, suggesting a high
specificity of anti-NAE autoantibodies to encephalopathy with
HT. One third of patients examined here did not have anti-NAE
Fig. 3. Neurological manifestations compared between patients with and without
anti-NAE autoantibodies. NAE(+), presence of anti-NAE autoantibodies; NAE(−),
absence of anti-NAEautoantibodies. C, consciousness disturbance; S, seizures; C/P,
cognitive impairment/psychiatric symptoms; I, involuntary movements: A, ataxia.
Fig. 4. Laboratory and MRI findings in patients.
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autoantibodies in their sera. NAE(−) patients can be associated
with different autoantibodies because our preliminary study
demonstrated other possible autoantibodies detected in NAE(−)
patients (data not shown, in progress).
In the neurological features of the patients examined here,
consciousness disturbance (80%), seizures (68%), cognitive
impairment/psychiatric symptoms (76%) and involuntary
movements (52%) were common in HE, while ataxia (12%)
was much less frequent. As the clinical form, acute encepha-
lopathy (AE) was the most common (76%). Chaudhuri and
Behan investigated 18 cases of HE clinically and immunolog-
ically, and indicated that headaches (90%), seizures (67%),
focal neurological deficit (67%), stupor/coma (67%), psychosis
(50%) were common and ataxia (16%) and hemiparesis (16%)
were rare (Chaudhuri and Behan, 2003). Although Chaudhuri
and Behan emphasized myelopathy as a common clinical
feature in HE with a similarity to ADEM, myelopathy was not
observed in patients examined in our study. In addition, the anti-
NAE autoantibodies were not detected in 4 patients with post-
infectious ADEM in our study, suggesting that the clinical form
of ADEM appeared relatively less frequent than Chaudhuri and
Behan supposed.
In this study, relapsing was less frequent (16%) than that in
Chaudhuri and Behan's study (67%). Chaudhuri and Behan
carefully followed-up their patients with HE over a period of
16 years, and clarified the outcome of HE patients (Chaudhuri
and Behan, 2003). The low frequency of relapse in our study
seemed to depend on the short periods of the clinical courses
examined (most patients were within one year). Thus, this short-
term observation could have caused an underestimation of the
relapse rate of HE in our study.
On laboratory/MRI findings in our study, EEG abnormalities
were common (90%), compared to the low prevalence of ab-
normalities on brain MRI (20%). Elevation in CSF protein/IgG
in our study was also a common feature (54%). Although
there was no major difference in patients between NAE(+) and
NAE(−) in the clinical features and laboratory/MRI findings in
the present study, EEG abnormalities appeared at higher fre-
quency and steroids tended to be more effective in NAE(+)
patients.
Chaudhuri and Behan recommend immunosuppressants (e.g.
azathioprine) as a potentially effective treatment besides ste-
roids from the perspective of T-cell sensation to the antigen in
HE (Chaudhuri and Behan, 2003). Although steroids have been
widely administered to patients with HE in our study and others,
steroid-responsiveness shows a temporally limited quality and
other immunosuppressant agents are necessary to sustain long-
term clinical response (Chaudhuri and Behan, 2003). Indeed, in
our patient (Case 24) who showed an excellent steroid-respon-
siveness on the initial attack but poor response on the following
attacks, this was successfully prevented from relapsing after the
administration of an immunosuppressant (azathioprine) was
started.
Chong et al. assumed that the combination of encephalop-
athy, presence of anti-thyroid antibodies and responsiveness to
steroid administration seemed unlikely to be due to chance,
and, however, there was no evidence of a pathogenic role for
anti-thyroid antibodies in encephalopathy associated with HT
(Chong et al., 2003). On the contrary, Ferracci et al. speculated
that autoimmunity to neural antigens cross-reacting with thy-
roid antigens was the pathogenic basis of encephalopathy with
HT (Ferracci et al., 2004). Additionally, the neuropathological
finding of an autopsied case and brain perfusion studies in
patients with HE suggested brain vasculitis, and supported the
disease entity of HE (Nolte et al., 2000; Zettinig et al., 2003;
Piga et al., 2004).
Sawka et al. searched for cases of encephalopathy associated
with HT in Mayo Clinic from 1950 to 1996 years, and assumed
that HE could be a rare autoimmune condition associated with a
common autoimmune HT, in part with unknown origin (Sawka
et al., 2002). In the present study, however, a large number of
cases of encephalopathy associated with HT were still present,
and two thirds of these patients carried anti-NAE autoantibodies
even after neurological specialists had carefully excluded other
possible conditions causing encephalopathy. Such discrepancy
may be driven from differences between the profiles of patients
treated by neurologists and compared to those treated by endo-
crinologists; i.e. neurologists see patients with neuropsychiatric
symptoms of various causes while endocrinologists more fre-
quently see patients with HTand less frequently encephalopathy.
Fatourechi et al. stated that a distinct clinical entity of ence-
phalopathy associated with HT was present but the use of the
term “Hashimoto's encephalopathy” was unfavorable until the
pathogenesis of this condition was better defined (Fatourechi,
2005). Although the pathogenic role for anti-NAE autoanti-
bodies in HE remained obscure, the present study demonstrated
that anti-NAE autoantibodies were more specific to HE than
anti-thyroid antibodies. This strongly suggests that “Hashimo-
to's encephalopathy” is a distinct clinical entity associated with
HT although the underlying immunological condition should be
better defined. Both the anti-NAE autoantibodies and anti-thy-
roid antibodies can be generated in the common immunological
background related to HT, such as T-cell mediated antibody
production (Weetman and McGregor, 1994; Stassi and De-
Maria, 2002).
In conclusion, anti-NAE autoantibodies, in addition to anti-
thyroid antibodies, are emphasized to as a useful serological
diagnostic marker of HE, and should be included in the diag-
nostic criteria of this condition. Physicians must more attentive-
ly consider the possibility of HE, and test serum for anti-NAE
autoantibodies as well as carefully excluding other conditions
causing encephalopathy in patients with HT.
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